Last Update:
March 27, 2018
Documents identified with this
icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
Journal Papers, Abstracts, and
Commentaries
| |
Patient characteristics associated with peglyated interferon alfa-2a induced
neutropenia in chronic hepatitis C patients.|
Hindi NN, Saleh MI.|
Clin Exp Pharmacol Physiol.
2018 Mar 25.
Abstract
Effects of Smoking on Pegylated Interferon alpha 2a and First Generation
Protease Inhibitor-based Antiviral Therapy in Naďve Patients Infected with
Hepatitis C Virus Genotype 1.
Zimmermann T, Hueppe D, Mauss S,
et al
J Gastrointestin Liver Dis.
2016 Mar;25(1):15-24.
Abstract
FULL-TEXT ARTICLE
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic
Infection with a High Probability of Sustained Virological Response to
Peginterferon Alfa-2a/Ribavirin.
Asselah T, Thompson AJ, Flisiak R
PLoS One.
2016 Mar 18;11(3):e0150569.
Paper
Hepatitis C Viral Kinetic Changes in a Retrospective Cohort
Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon
and Ribavirin Therapy.
Esmat GE, Al Akel W, Abdel Aziz RA, et al
J Interferon Cytokine Res.
2016 Mar;36(3):149-58
Abstract
Reduction in Hepatic Inflammation Is Associated With Less
Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
Morishima C, Shiffman ML, Dienstag JL, et al
Am J Gastroenterol. 2012 Jun 12.
Abstract
Factor VIII and IX deficiencies related to acquired inhibitors
in a patient with chronic hepatitis C virus infection receiving treatment with
pegylated interferon plus ribavirin.
Campos-de-Magalhăes M, Eduardo
Brandăo-Mello C,
et al
Hematology. 2011 Mar;16(2):80-5.
Abstract
Nitric oxide levels and sustained virological response to pegylated-interferon
alpha2a plus ribavirin in
chronic HCV genotype 4 hepatitis: A prospective study.
Ibrahim M, Gomaa W, Ibrahim Y, et al
J Gastrointestin Liver Dis.
2010 Dec;19(4):387-92.
Abstract |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for
the treatment
of dual chronic infection with hepatitis B and C viruses.
Yu ML, Lee CM, Chuang WL, et al
J Infect Dis. 2010 Jul 1;202(1):86-92.
Abstract |
Human leukocyte antigen alleles and the response to pegylated
interferon/ribavirin
therapy in chronic hepatitis C patients.
Dai CY, Chuang WL, Hsieh MY, et al
Antiviral Res.
. [Epub ahead of print]
Abstract |
Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b
or not 2b (= 2a),
that is the question?'
Toyoda H, Kumada T.
Expert Opin Pharmacother.
2009 Nov 6.
Abstract |
Insulin resistance predicts response to peginterferon-alpha/ribavirin
combination therapy in chronic
hepatitis C patients.
Dai CY, Huang JF, Hsieh MY,
et al
J Hepatol. 2009 Feb 6.
Abstract
|
|
Journal Papers, Abstracts, and
Commentaries
Journal Papers, Abstracts, and
Commentaries
|
Peg Interferon alfa-2a
Journal Papers, Abstracts, and
Commentaries
|
| |
Predictors of Virological Response in 3,235 Chronic HCV Egyptian Patients
Treated with Peginterferon Alpha-2a Compared with Peginterferon Alpha-2b
Using Statistical Methods and Data Mining Techniques.
El Raziky M, Fathalah WF, Zakaria Z,
et al
J Interferon Cytokine Res.
2016 Feb 9.
Abstract
FULL-TEXT ARTICLE
Treatment of Naďve Patients with Chronic Hepatitis C Genotypes 2 and 3 with
Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance
for the New Era of DAA.
Heidrich B, Wiegand SB, Buggisch P, et al
PLoS One.
2014 Oct 10;9(10):e108751.
Paper
Pegylated Interferon-α2a With or Without Low-Dose Ribavirin for
Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving
Hemodialysis: A Randomized Trial.
Liu CH, Huang CF, Liu CJ, et al
Ann Intern Med.
2013 Dec 3;159(11):729-38.
Abstract
The Combination of Ribavirin and Peginterferon Is Superior to
Peginterferon and Placebo for Children
and Adolescents Chronic Hepatitis C.
Schwarz KB, Gonzalez-Peralta RP, Murray KF, et
al
Gastroenterology.
2010 Oct 28.
Abstract |
Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus
ribavirin in
the daily routine treatment of patients with chronic hepatitis C in
Germany:
The PRACTICE Study.
Witthoeft T, Hueppe D, John C, et al
J Viral Hepat.
2010 Jul;17(7):459-68.
Abstract |
Pegylated Interferons for the Treatment of Chronic Hepatitis C:
Pharmacological and
Clinical Differences between Peginterferon-alpha-2a and
Peginterferon-alpha-2b.
Foster GR.
Drugs.
2010;70(2):147-65.
Abstract |
Spotlight on peginterferon-alpha-2a (40 kD) plus
ribavirin in the management of chronic hepatitis C mono-infection.
Keam SJ, Cvetković RS.
BioDrugs.
2009;23(1):63-8
Abstract |
FULL-TEXT PDF ARTICLE
Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous
viral clearance, and
delayed treatment with 12 weeks of pegylated interferon alfa-2a.
Sharaf Eldin N, Ismail S, et al
PLoS ONE. 2008;3(12):e4085.
Paper
|
Peginterferon-alpha(2a) (40 kDa) for chronic hepatitis C.
Hadziyannis SJ, Papatheodoridis GV.
Expert Opin Pharmacother
2003 Apr;4(4):541-551
Abstract
|
|
|
Peg Interferon alfa-2a/Ribavirin
Journal Papers, Abstracts, and
Commentaries
|
| |
Pegylated interferon
α/ribavirin therapy enhances
bone mineral density in
children with chronic
genotype 4 HCV infection
Megahed A, Salem N, Fathy A,
et al
World J Pediatr.
2017 Jan 27.
Abstract
Optimisation of triple therapy for patients with chronic hepatitis C: a
systematic review.
Pecoraro V,
Cariani E, Villa E, Trenti T.
Eur
J Clin Invest.
2016 Aug;46(8):737-48.
Abstract
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for
Treatment-Naďve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized
Trial.
Liu CH, Huang CF, Liu CJ, et al
Sci Rep. 2015 Oct
15;5:15255.
Abstract
Psychomotor retardation and vulnerability to interferon alpha induced major
depressive disorder: Prospective study of a chronic hepatitis C cohort.
Whale R, Fialho R, Rolt M, Eccles J, et al
J Psychosom Res. 2015 Jun 18
Abstract
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in
chronic hepatitis C: final analysis from the PROPHESYS cohort.
Aronsohn A, Ancuta I, Caruntu F, et al
J Viral Hepat.
2013 Oct 17.
Abstract
Faldaprevir combined with peginterferon alfa-2a
and ribavirin in treatment-naďve patients with chronic genotype-1 HCV:
SILEN-C1 trial.
Sulkowski MS,
Asselah T, Lalezari J, et al
Hepatology.
2013 Jan 28.
Abstract
FULL-TEXT
PDF ARTICLE
Prediction
of response to pegylated-interferon-ż and ribavirin therapy in Chinese
patients infected with different hepatitis C virus genotype.
Guo X, Zhao Z, Xie J, et ak
Virol J. 2012 Jun
19;9(1):123.
Paper
Randomized controlled trial of pegylated interferon-alfa 2a and
ribavirin in treatment-naive chronic
hepatitis C genotype 6.
Lam KD, Trinh HN, Do ST, et al
Hepatology.
2010 Nov;52(5):1573-80.
Abstract |
Intensified peginterferon alfa-2a/ribavirin therapy for patients with HCV
genotype 1,
weight >/=85 kg and high viral load: randomized trial.|
Reddy KR, Shiffman ML,
Rodriguez-Torres M,, et al
Gastroenterology. 2010 Sep 2
Abstract |
Individualized respond guidance treatment of chronic hepatitis C with
combination of
peginterferon a-2a and ribavirin.
Chen WL, Chen XP, Chen XF, et al
Zhonghua Gan Zang Bing Za Zhi.
2010 Aug;18(8):585-9
Abstract |
A sustained virologic response is durable in patients with chronic hepatitis C
treated with peginterferon alfa-2a and ribavirin.
Swain MG, Lai MY, Shiffman ML, et al
Gastroenterology.
2010 Jul 13.
Abstract |
High rates of sustained virological response in hepatitis C virus-infected
injection drug users
receiving directly observed therapy with peginterferon alpha-2a (40KD)
(PEGASYS)
and once-daily ribavirin.
Waizmann M, Ackermann G.
J Subst Abuse Treat. 2010 Mar 31
Abstract |
Effect of HCV RNA suppression during peginterferon Alfa-2a maintenance therapy
on clinical outcomes
in the HALT-C trial.
Shiffman ML, Morishima C, Dienstag
JL, et al
Gastroenterology.
2009 Dec;137(6):1986-94.
Abstract |
Peginterferon Alpha-2a Plus Ribavirin is More Effective than Peginterferon
Alpha-2b Plus Ribavirin
for Treating Chronic Hepatitis C Virus Infection.
Ascione A, De Luca M, Tartaglione MT, et al
Gastroenterology.
2009 Oct 20.
Abstract |
Randomized Study of Peginterferon-alpha2a Plus Ribavirin Versus
Peginterferon-alpha2b Plus Ribavirin
in Chronic Hepatitis C.
Rumi M, Aghemo A, Prati
GM, et al
|
Gastroenterology.
2009 Sep 17
Abstract |
Effect of HCV RNA Suppression During Peginterferon Alfa-2A Maintenance
Therapy on Clinical
Outcomes in the HALT-C Trial.
Shiffman ML, Morishima C,
Dienstag JL, et
al
Gastroenterology. 2009 Sep 9.
Abstract |
FULL-TEXT PDF ARTICLE
Assessment
of the efficacy of reducing peginterferon alfa-2a and ribavirin dose on
virologic response in koreans with chronic hepatitis
C.
Kwon JH,
Bae SH, Choi JY, et al
Korean J Intern Med.
2009 Sep;24(3):203-11
Paper |
Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained
virological response
in sub-sets of older
and younger HCV genotype 1 patients.
Reddy KR, Messinger D, Popescu M, Hadziyannis
SJ.
J Viral Hepat. 2009 Mar 25
Abstract |
Eradication of hepatitis C virus after a 5-week treatment
Gaundong Mbéthé GL,
Foucher J, Deledinghen V, Couzigou VP.
Rev Med Interne. 2009 May
18.
Abstract |
Treatment of hepatitis C virus carriers with persistently normal alanine
aminotransferase levels
with peginterferon
alpha-2a and ribavirin: a multicentric study.
Puoti C, Pellicelli AM, Romano M, et al
Liver Int. 2009 Apr 17.
Abstract |
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon
{alpha}2b plus ribavirin for the
treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J, González-García J, López-Aldeguer J, et al
J
Antimicrob Chemother.
2009 Apr 10
Abstract |
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon
{alpha}2b plus ribavirin for the
treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J, González-García J, López-Aldeguer J, et al
J Antimicrob Chemother.
2009 Apr 10
Abstract |
Factors affecting early viral load decline of Asian chronic hepatitis C patients
receiving pegylated interferon plus
ribavirin therapy.
Hsu CS, Liu CH, Liu CJ,
et al
Antivir Ther. 2009;14(1):45-54.
Abstract |
Peginterferon and ribavirin in HCV: improvement of sustained viral
response.
Ferenci P.
Best Pract Res Clin Gastroenterol.
2008;22(6):1109-22.
Abstract
|
|
|
|
P eg Interferon alfa-2a/Ribavirin/Rituximab
Journal Papers, Abstracts, and
Commentaries
Peg Interferon alfa-2a
vs
Standard Interferon
alfa-2a
Journal
Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and
Commentaries
|
New
and Noteworthy
HIV/HCV
Coinfection
Main
New/Newsworthy
